Compare Adobe Systems Inc (ADBE) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adobe Systems Inc vs TG Therapeutics Inc — how do they compare? Adobe Systems Inc trades at $219.74 (market cap $88.06B), while TG Therapeutics Inc trades at $56.78 (market cap $8.89B). The key difference: Adobe Systems Inc is far larger — about 9.9× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Adobe Systems Inc nearer its low. Which is the better fit depends on your goals.
| ADBE | TGTX | |
|---|---|---|
Market Cap | $88.06B | $8.89B |
Volume | 5,187,646 | — |
Sector | Technology | Health |
52-Week High | $382.24 | $58.06 |
52-Week Low | $193.41 | $26.39 |
Enterprise Value | $89.50B | $9.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adobe (ADBE) trades at $219.75, up 0.77% with strong fundamentals including 29.99% net margin and consistent earnings beats. The stock shows bullish technical signals despite recent volatility, with support at $218 and resistance at $228. Revenue growth accelerated to $23.77B in 2025, while institutional activity remains mixed amid AI competition concerns.
ADBE presents a compelling value opportunity with a 12.67 P/E ratio and 49% analyst buy ratings, though AI disruption fears and CEO transition create near-term uncertainty. The consensus price target of $246.75 implies 12% upside potential, balanced against sector-wide software pressures.
TGTX trades at $55.47, up 4.05% today, with a bullish technical signal from moving averages and strong fundamental profitability. Revenue grew to $616.29M in 2025 with a net income margin of 65.95%, though recent quarterly EPS missed expectations. Positive news includes a new Phase II study for Briumvi in schizophrenia and strong sales momentum.
Outlook is positive driven by Briumvi's expansion, but risks include clinical trial outcomes and earnings volatility. Analysts are bullish with 84.6% buy ratings. The stock's high valuation multiples warrant monitoring of execution against growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adobe Systems Inc
Adobe Inc. develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. Adobe offers a line of application software products, type products, and content for creating, distributing, and managing information.
Read more on ADBE →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
